Calliditas announces an seven year orphan drug exclusivity period for TARPEYO®
STOCKHOLM, Feb. 21, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
STOCKHOLM, Feb. 14, 2024 /PRNewswire/ -- Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday 21 February 2024 at 07.00 a.m. CET.
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
Calliditas announces additions to the management team